A total of 15 Mycoplasma gallisepticum (MG) isolates from Chinese poultry farms and three reference strains (S6, BG44T, and F36) were characterized by nested polymerase chain reaction and sequence analysis for two identical and directly repeated sequences, DR-1 and DR-2, within the putative cytadhesin pvpA gene. The molecular variation patterns of the pvpA genes among the 15 MG isolates were identical to the reference strains S6 and BG44T, that is, a 60 bp deletion in DR-1 and DR-2 and repetition of 1) a proline residue 33 times and 2) a tetrapeptide motif 10 times (Pro-Arg-Pro-X, where X is Met, Gly, Asn, or Gln for 6, 1, 1, or 2 times, respectively). However, the variation pattern is quite different from that of the vaccine strain F36, in which only the DR-1 Region is retained, 24 of the 25 peptides comprising the linkage sequence between DR-1 and DR-2 are missing, and the entire DR-2 sequence is deleted. A comparison of the sequences within the DR-1 and DR-2 repeated Regions among clinical isolates from different geographic sites suggested that ≥30 proline residue repeats and 7–10 repeats of the tetrapeptide motif may exert an important role in the functionality of PvpA as an adhesin molecule. Size variation and differences in deletion patterns in the C-terminal coding Region of the pvpA gene were observed among the field isolates and vaccine strain F, providing the basis for strain differentiation.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 53 • No. 1